WO1994010205A1 - Proteine specifique de la maladie d'alzheimer et procede de diagnostic de cette maladie par detection de ladite proteine - Google Patents

Proteine specifique de la maladie d'alzheimer et procede de diagnostic de cette maladie par detection de ladite proteine

Info

Publication number
WO1994010205A1
WO1994010205A1 PCT/JP1993/001503 JP9301503W WO9410205A1 WO 1994010205 A1 WO1994010205 A1 WO 1994010205A1 JP 9301503 W JP9301503 W JP 9301503W WO 9410205 A1 WO9410205 A1 WO 9410205A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
disease
alzheimer
antibody
electrophoresis
Prior art date
Application number
PCT/JP1993/001503
Other languages
English (en)
Japanese (ja)
Inventor
Kiminobu Sugaya
Hiroshi Marusawa
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to AU51574/93A priority Critical patent/AU5157493A/en
Publication of WO1994010205A1 publication Critical patent/WO1994010205A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Definitions

  • the present invention relates to a specific protein relating to Alheimer's disease and a method for diagnosing Alheimer's disease by detecting the protein.
  • the present invention relates to a protein, an antibody recognizing the protein and a fragment of the protein, and a method for diagnosing Alzheimer's disease using the antibody or the protein, which is useful for the study of diagnosis, cause and treatment of Alzheimer's disease. It is related to kits used in the medical field.
  • Alzheimer's disease mainly develops in the elderly and elderly, with progressive dementia as the main symptom, as well as mental symptoms and problem behaviors associated with dementia, such as excitement, violence, wandering, hallucinations, delusional insomnia, delirium, etc. It is symptomatic and pathologically characterized by general brain atrophy, extensive neuronal loss, senile plaques, amyloid protein deposition, and the presence of neurofibrillary tangles. In today's aging society, Alzheimer's disease is one of the social problems. No cure has been found for Alzheimer's disease at present, but drugs such as neurotransmitters and related substances, brain stimulants, and cerebral circulation improvers are being developed to halt and improve the progress of the disease.
  • the progression of the disease is usually very slow and there is no subjective symptom, so it is often too late to treat when the surrounding people notice the dementia symptoms of the patient.
  • Examples of various biological markers include, for example, a tau protein (Lee VL, eta1: Science, 251, and A68 with a molecular weight of 68,000) extracted from the brain of Alzheimer's disease patients. 6 7 5-6 7 8, 1 9 9 1) Insoluble /? 4 protein from brain-derived amyloid from patients with D. Alzheimer's disease (Masters CL, eta 1: Proc. Natl) ...
  • a ca d S ci USA, 8 2, 4 2 4 5 - 4 0 2 4 9, 1 9 8 5) include, antibodies that react to these (Wo 1 ozin BL, eta 1 : S cience, 2 3 2,6 4 8-6 5 0, 1 9 8 6), (A 11 sop D, etal: N eurosci Lett, 68, 25 2-2 56, 1 9 8 6) Have been. However, it has not been sufficiently confirmed that these proteins are always present only in patients with Alzheimer's disease and not present in persons without Alzheimer's disease 5 (hereinafter referred to as “normal persons”).
  • Definitive diagnosis of Alzheimer's disease in the brain It is desired to establish a simple and early method for early diagnosis of Alzheimer's disease using the method and samples obtained from the periphery of the subject, such as blood, skin, hair, and nasal mucosa. Disclosure of the invention
  • the inventors of the present invention have studied proteins expressed in the brains of Alzheimer's disease patients and normal subjects, and as a result, found proteins that are detected in the brains of Alzheimer's disease patients and are not detected in the brains of normal subjects.
  • this protein has a relatively small molecular weight and is water-soluble, it has been found that there is a high possibility that it is specifically detected in patients with Alzheimer's disease in the periphery as well as in the brain.
  • An antibody recognizing this protein or a fragment of the protein is prepared using the protein or a peptide synthesized from the N-terminus of the protein obtained by sequence analysis in accordance with the amino acid sequence as an antigen, and the antibody and Alzheimer's disease are prepared.
  • the protein expressed in the brain and the like of the patient with the above, and by detecting this reaction, it was found that a definite diagnosis of Alzheimer's disease can be made relatively easily.
  • the present invention was completed by producing a kit used for this diagnosis. This invention is divided into the following four inventions.
  • [I] A protein obtained from at least the brain of a patient with Alzheimer's disease and having the following properties.
  • [II] An antibody that recognizes the protein of [I] or a fragment of the protein.
  • [III-1] reacting a sample collected from a subject with at least one antibody that recognizes the protein of [I] or a fragment of the protein, and detects the degree or presence or absence of the reaction. To diagnose Alzheimer's disease.
  • [I I I 1-2] A method for diagnosing Alzheimer's disease, comprising analyzing a sample collected from a subject to check for the presence or amount of the protein of [I].
  • the composition includes at least one antibody recognizing the protein of [I] or a fragment of the protein, and means for detecting a reaction between the antibody and a sample collected from a living body.
  • a diagnostic kit for Alzheimer's disease As a component, the composition includes at least one antibody recognizing the protein of [I] or a fragment of the protein, and means for detecting a reaction between the antibody and a sample collected from a living body.
  • the protein of the present invention can be obtained from at least the brain of Alzheimer's disease patients, and can be obtained, for example, by extracting from the brain of a dead Alzheimer's disease patient.
  • an aqueous solvent for example, various buffers (HEPES buffer, etc.) is preferable.
  • This protein can be extracted by collecting, for example, the cerebral cortex from the brain of a dead Alzheimer's disease patient, adding the aqueous solvent described above, homogenizing, and then centrifuging under cooling to obtain a supernatant.
  • Separation of this protein from the supernatant can be performed by two-dimensional electrophoresis in a conventional manner.
  • This protein of interest is determined as a spot of the protein detected in Alzheimer's disease patients by comparing it with the electrophoresis pattern obtained from the brain of a normal person through the same method.
  • the properties of this protein are determined by the method described in the examples below.
  • the target protein can be extracted from the two-dimensional electrophoresis gel by subjecting it directly to coomassie-prilian-blue staining.
  • This protein is a protein having the following properties.
  • the protein of the present invention is not limited to the protein obtained from the brain of an Alzheimer's disease patient, but also includes the protein obtained from a part other than the brain of a living body or by a genetic recombination technique.
  • the antibody used in the method for diagnosing Alzheimer's disease of the present invention recognizes the protein or the fragment of the protein detected from the Alzheimer's disease patient of the above [I].
  • a fragment of the protein includes a part of the amino acid sequence contained in the protein, a sugar chain that modifies the protein, and the like.
  • This antibody can be either polyclonal or monoclonal and can be prepared by methods well known in the art, but monoclonal antibodies are preferred.
  • the polyclonal antibody against the protein of the present invention is obtained by administering an animal such as a heron to a peptide synthesized by the Fm0c solid phase method or the like according to the amino acid sequence from the N-terminal of the protein or the protein obtained by sequence analysis. After immunization, it can be obtained by subjecting the resulting antiserum to isolation and purification by subjecting it to conventional procedures such as salting out ammonium sulfate or the like, centrifugation, dialysis, and column chromatography.
  • a monoclonal antibody can be used in an animal such as a mouse in accordance with, for example, the method of Cola and Milstein (Kohler & MiIstein: Nature, 256, 495-497, 19775).
  • a peptide synthesized from the N-terminus of the protein obtained by sequence analysis according to the amino acid sequence such as the Fm0c solid phase method and the like is administered and immunized, and then spleen cells are obtained from the spleen. Cell fusion with mouse myeloma cells, etc. To get Hypri-Dorma.
  • a hybridoma producing a monoclonal antibody specific to the protein of the present invention is screened, and an antibody most suitable for discriminating between Alzheimer's disease patients and normal subjects is screened out of the hybridomas.
  • Subcloning a hybridoma that produces an antibody that does not react with the protein of interest is obtained by isolating and purifying from the subcloned culture supernatant or the like in the same manner as the above-mentioned polyclonal antibody. .
  • the method for diagnosing Alzheimer's disease comprises the steps of: using a sample collected from the subject's brain or a Q organism other than the brain, such as cerebrospinal fluid, blood, skin, hair, etc. It is characterized by reacting at least one kind of antibody that recognizes a fragment of the protein and detecting the degree or presence or absence of the reaction.
  • a case where this protein or a protein having a fragment of the protein is detected by the antibody of the present invention in a sample of a subject is a case where Alzheimer's disease or a sign thereof is present or not detected.
  • a normal person can be diagnosed.
  • the amount of this protein gradually increases in the process of developing Alzheimer's disease in normal individuals.
  • the protein or a protein having a fragment of the protein is detected in the sample of the subject by the antibody of the present invention in a predetermined amount or more, Alheimer's disease or a sign thereof is diagnosed. You can also.
  • the sample When the subject's brain is used as a sample, the sample is homogenized in a buffer, centrifuged, and the supernatant is collected. The supernatant is reacted with the antibody of the present invention.
  • the sample is immobilized in 10% neutral buffered formalin and then reacted with the antibody of the present invention.
  • Methods for detecting the reaction include Enzymlink Immunosorbent Assay (ELISA), Enzyme Imuno Assay (EIA), Fluorescent Imuno Assay (FIA), Radioimino Assay (RIA), and Chemiluminescence immunoassay. (CLIA), chemiluminescent enzyme immunoassay (CLEIA), latex agglutination, and the like.
  • ELISA Enzymlink Immunosorbent Assay
  • EIA Enzyme Imuno Assay
  • FIA Fluorescent Imuno Assay
  • RIA Radioimino Assay
  • CLIA Chemiluminescence immunoassay
  • CLIA chemiluminescent enzyme immunoassay
  • latex agglutination and the like.
  • the presence or amount of the protein [I] is analyzed by analyzing a sample of a subject.
  • Examples of the analysis method at this time include an electrophoresis method (for example, a two-dimensional electrophoresis method), various chromatography methods (for example, a high-performance liquid chromatography method), a bioassay method, and the like.
  • an electrophoresis method for example, a two-dimensional electrophoresis method
  • various chromatography methods for example, a high-performance liquid chromatography method
  • a bioassay method and the like.
  • a sample of a subject is extracted by the same method as in the above [I]
  • the obtained gel is subjected to silver staining or the like according to a conventional method, or To the ⁇ ⁇ stamp lot, incubate the blotting membrane and the antibody of [II] above at room temperature, and then add the labeled secondary antibody.
  • the spots of the protein of [I] are detected to some extent or more than a predetermined amount from the electrophoresis pattern, Alzheimer's disease or a sign thereof can be diagnosed.
  • the kit used for the diagnosis of Alzheimer's disease of [III-1] is composed of at least one antibody that recognizes the protein of [I] or a fragment of the protein as a component, and the antibody and the brain or other than brain. It is characterized by including means for detecting a reaction with a sample collected from a living body.
  • Examples of the antibody used include a polyclonal antibody [I I] and a monoclonal antibody, and a monoclonal antibody is preferable.
  • Methods using one type of antibody include, for example, immunohistochemical techniques (eg, EIA), and methods using two types of antibodies include, for example, ELISA using the sandwich method. .
  • Means for detecting the reaction include those used in the detection method described in [III-11].
  • enzyme-labeled anti-mouse IgG, substrate examples include a buffer solution, a blocky antibody (eg, goat serum), and in the case of ELISA, an enzyme-labeled anti-mouse IgG, a substrate, a carrier (eg, beads, plates, etc.), a buffer solution, a reaction stop solution, and the like.
  • Fig. 1 is a photograph showing a silver-stained secondary electrophoresis gel of a sample of an Alzheimer's disease patient (A1 zheimer's Disease) (left) and a sample of a normal person (Contro1) (right). .
  • the arrow indicates the protein of the present invention detected in Alzheimer's disease patients. It shows that it is not detected by ordinary people.
  • the numbers displayed in the center vertically indicate the molecular weight (kD) of the molecular weight marker, and the numbers displayed in the lower side indicate the isoelectric point (pi) of the isoelectric point marker.
  • FIG. 2 is a photograph of immunostaining of an Alzheimer's disease patient using the antibody of the present invention.
  • FIG. 3 is a photograph of immunostaining of a normal person using the antibody of the present invention.
  • the arrow in FIG. 2 indicates the protein of the present invention detected in the Alzheimer's disease patient recognized by the antibody of the present invention, which is recognized at the same position as in the case of the silver staining shown in FIG. 1, and the normal person in FIG. Indicates that it has not been detected.
  • the present invention will be described in detail with reference to examples.
  • HEPS buffer containing 25 mM HEPES, 0.25 mM EDTA, 50 mM magnesium chloride: PH6,8.
  • Electrophoresis was performed by isoelectric focusing using Investigator 2—DE electrophoresis system (manufactured by Nippon Millipore) as the electrophoresis device, and sodium dodecyl sulfate—polyacrylamide is used for secondary electrophoresis. Electrophoresis (SDS-PAGE) was performed.
  • the primary electrophoresis gel was prepared as follows.
  • the first electrophoresis was performed using 85% phosphoric acid as the anolyte and 10 N-sodium hydroxide as the catholyte.
  • Overlay buffer [0.5 M urea, 0.2% (V / V) N 0 nidet P—40, 0.1% (V / V) Am pho 1 ite, 5.0 mM DTT, 0. [M M—Mercaptoethanol] was layered in 101 layers, and pre-electrophoresis was performed at room temperature for 2 hours at a maximum voltage of 150 V and a maximum current of 110 A / ge 1.
  • the protein sample from the cerebral cortex prepared in Example 1 was layered between the overlay buffer and the gel in a layer of 101, and the maximum voltage was set to 200 V and the maximum current was set to 110 ⁇ A / ge1. Electrophoresis was performed at room temperature until Volt — Ours reached 180 000 V. As an isoelectric point marker, IEF manufactured by Biorad Standards (PI 4.6 to 9.6) were used.
  • the one-dimensional gel is taken out in 10% glycerin, and the one-dimensional gel equilibration buffer (0.3 MT ris Base, 0.075 MT ris HC 1, 3%) is taken for 2 minutes. After equilibration in sodium dodecyl sulfate (SDS), 50 mM DTT, 0.1% bromphenol blue), it was placed on a secondary electrophoresis gel.
  • SDS sodium dodecyl sulfate
  • the secondary electrophoresis gel was Duracry 1 (manufactured by Nippon Millipore) 29.6 lml, Tris buffer (130.8 g / 1 Tris Base, 66.3 g / l Tris) HC 1) 2 20.5 ml, M i 1 1i- Q water 3 65.4 ml, 10% SDS 9.0 ml, tetramethylethylenediamine (TEMED) 0.447 ml, 2.24 ml of 10% APS was mixed and prepared to a thickness of 1 mm between 26 ⁇ 26 cm glass plates.
  • the two-dimensional electrophoresis buffer was adjusted with the composition of 25 mM Tris Base, 19 2 mM glycine, 0.1% SDS, and the electrophoresis was performed at 20 ° C at a maximum voltage of 500 V and maximum power. The procedure was performed at 1,600 mW / ge 1 until the stained surface became 1 cm from the bottom of the gel.
  • an SDS-PAGE standard (Low, MW 1440000 to 9-740) manufactured by Piorad was used.
  • Example 2 (2) In order to detect proteins expressed in Alzheimer's disease patients, the secondary electrophoretic gel obtained in Example 2 (2) was silver-stained by a conventional method.
  • Fig. 1 shows secondary electrophoresis gels of each sample of Alzheimer's disease patients and normal subjects stained with silver.
  • the isoelectric point and molecular weight of this protein specific to Alzheimer's disease patients were determined by comparison with the respective markers.
  • the protein specifically detected in this Alzheimer's disease patient was subjected to plotting in order to determine the N-terminal amino acid sequence.
  • For plotting use Imm obilon (manufactured by Nippon Millipore) for the membrane, and use Mi 1 iB10t (manufactured by Nippon Millipore) for the blotter. 50 A / sq-cm) and a maximum power of 100 W for 30 minutes.
  • the blotting membrane was stained with PhastGelBlueR (Pharmacia) to cut out the target spots.
  • PhastGelBlueR PhastGelBlueR
  • the protein in this spot was analyzed by an ordinary method using Applied Biosystems' 477 APRoitenSeeqenccer and 120 AAnalyzer.
  • amino acid sequence up to the 15th residue from the N-terminus of the protein specific to this Alzheimer's disease patient is, as shown in the sequence listing below,
  • the amino acid sequence (Ala-A1a-Val-Pro-Ser-Gly-A1a—Ser-Thr-) obtained by the sequence analysis of the protein spot of Example 3 (2) Based on G 1 y-I 1 e-T yr-G lu-A 1 a-Leu), Proc. Natl. Acad. Sci USA (Vo186, 90084)
  • the peptide was synthesized by the Fmoc solid-phase method using Advanced ChemTec 350 according to the method described in 99088).
  • the peptide was synthesized from the C-terminal side to the N-terminal side together with a polystyrene resin with a MAP core.
  • N, N-Dimethylformamide (DMF) was used as the system solution, and 20% piperidine was used to deprotect 1-hydroxybenzotriazole (HO bt) and 1,3-diisopropylcarbodiimide (DIC).
  • HO bt 1-hydroxybenzotriazole
  • DIC 1,3-diisopropylcarbodiimide
  • the synthesized peptide was washed with methanol and dried. After separation from the resin, the protecting groups on the side chains were removed using a solution of 90% trifluoroacetic acid, 5% trianisole, 3% ethanedithiol, and 2% anisol. The resulting peptide was washed five times with ether, dissolved in purified water, freeze-dried and stored until use.
  • the first immunization was carried out by subcutaneously injecting 0.5 mg of the peptide synthesized in this way into 20 egrets together with Freund's vaccine leteadjvant.
  • the second immunization was performed in the same manner by subcutaneously injecting 20 mg of 0.5 mg in a dose together with Freundsinco mp leteadjvant, blood was subsequently collected from the ear, and centrifuged to collect serum. Obtained. Using the polyclonal antibody contained in this serum as the primary antibody, the following test was performed.
  • Example 2 Separation of cerebral cortical water-soluble proteins using high-resolution two-dimensional electrophoresis was performed by primary electrophoresis in the same manner as in Example 2 (1), and then in the same manner as in Example 2 (2). Secondary electrophoresis was performed to obtain a two-dimensional electrophoresis gel.
  • MI LLIPO RE Immo bilon-P
  • MILLI PO RE Mi 1 i Blot
  • the test was performed at a maximum power of 100 W for 30 minutes.
  • the blotting membrane was stored frozen at 180 ° C and then returned to room temperature in 20 mM Tris saline (TBBS) containing 0.1% Tween-20. After washing three times with TBBS, the blotting membrane was incubated for 24 hours at room temperature with the above-mentioned antibody (primary antibody) diluted 1: 1000. After washing three times with TBBS, the cells were incubated for 1 hour and 30 minutes with a goat antibody (secondary antibody) of an alkaline phosphatase-labeled anti-magpie antibody.
  • the immunostaining using the antibody of the present invention is relatively easy to distinguish between Alzheimer's disease patients and normal subjects by two-dimensional electrophoresis because of its higher sensitivity and less staining of other proteins than silver staining. I can do it.
  • this antibody can be used, for example, as one antibody when performing the ELASA (sandwich) method to examine the presence or amount of a protein specifically expressed in this Alzheimer's disease patient in a subject sample. it can.
  • the protein of the present invention can be obtained from at least the brain of Alzheimer's disease patients, and is detected in Alzheimer's disease patients but not in normal persons. Therefore, an antibody useful for diagnosing Alzheimer's disease using this protein Can be adjusted. In addition, this protein is expected to be of great use in studies such as investigating the causes of Alzheimer's disease.
  • the antibody of the present invention recognizes the protein of the present invention or a fragment thereof which is expressed in the brain of a patient with Alzheimer's disease or a living body other than the brain, and reacts with the protein or a protein having a fragment of the protein to diagnose Alzheimer's disease.
  • the degree or presence or absence of a reaction with a sample is detected using the above-described antibody of the present invention, so that a definitive diagnosis of Alzheimer's disease in the brain or the like can be easily performed. .
  • it is highly likely that early diagnosis of Alzheimer's disease can be easily performed using peripheral samples. You.
  • a sample collected from a subject is analyzed to check for the presence or amount of the protein of the present invention, so that diagnosis of Alzheimer's disease can be performed only reliably. And an early diagnosis can be made.
  • Fragment type N-terminal fragment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à un procédé de diagnostic de la maladie d'Alzheimer et à une trousse à cet effet, par la détection d'une protéine que l'on trouve chez les patients souffrant de la maladie d'Alzheimer mais pas chez des sujet normaux, et consistant à utiliser la protéine ou un anticorps reconnaissant des fragments de cette dernière. La protéine présente les caractéristiques suivantes: (1) masse moléculaire: 30 kD, déterminée par électrophorèse sur gel de sulfate de sodium dodécyle-polyacryalamide; (2) point isoélectrique (pI): 6,9; et (3) séquence d'acides aminés au niveau de la terminaison N correspondant à la formule (α) dans laquelle Xaa représente un reste d'acide aminé non identifié.
PCT/JP1993/001503 1992-10-23 1993-10-19 Proteine specifique de la maladie d'alzheimer et procede de diagnostic de cette maladie par detection de ladite proteine WO1994010205A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU51574/93A AU5157493A (en) 1992-10-23 1993-10-19 Protein specific for alzheimer's disease and method of diagnosing alzheimer's disease through detection of the protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30941192 1992-10-23
JP4/309411 1992-10-23

Publications (1)

Publication Number Publication Date
WO1994010205A1 true WO1994010205A1 (fr) 1994-05-11

Family

ID=17992689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1993/001503 WO1994010205A1 (fr) 1992-10-23 1993-10-19 Proteine specifique de la maladie d'alzheimer et procede de diagnostic de cette maladie par detection de ladite proteine

Country Status (2)

Country Link
AU (1) AU5157493A (fr)
WO (1) WO1994010205A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088208A1 (fr) * 2005-02-21 2006-08-24 Dainippon Sumitomo Pharma Co., Ltd Procede d’evaluation d’un changement physiologique dans un corps vivant et appareil
US9938330B2 (en) 2012-03-29 2018-04-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Nanoscale process to generate reagents selective for individual protein variants
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04252195A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd モノクローナル抗体及びハイブリドーマ
JPH04505865A (ja) * 1989-06-01 1992-10-15 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アルツハイマー病診断測定法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04505865A (ja) * 1989-06-01 1992-10-15 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー アルツハイマー病診断測定法
JPH04252195A (ja) * 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd モノクローナル抗体及びハイブリドーマ

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088208A1 (fr) * 2005-02-21 2006-08-24 Dainippon Sumitomo Pharma Co., Ltd Procede d’evaluation d’un changement physiologique dans un corps vivant et appareil
JPWO2006088208A1 (ja) * 2005-02-21 2008-07-10 大日本住友製薬株式会社 生体の生理変化の予測方法および装置
US9938330B2 (en) 2012-03-29 2018-04-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Nanoscale process to generate reagents selective for individual protein variants
USRE49625E1 (en) 2012-03-29 2023-08-29 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Nanoscale process to generate reagents selective for individual protein variants

Also Published As

Publication number Publication date
AU5157493A (en) 1994-05-24

Similar Documents

Publication Publication Date Title
KR100595494B1 (ko) 혈액 내 베타-아밀로이드 항체 농도를 이용한 알츠하이머병 진단키트
CN101137670A (zh) 用单克隆抗体体外诊断阿尔茨海默病的方法
CN101215323B (zh) 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用
KR20130102688A (ko) 유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
US20200057079A1 (en) Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders
CA2088050A1 (fr) Detection de la necrose de cellules axee sur la spectrine et ses produits de decomposition
US6884873B2 (en) Kit for determining DNA double-stranded breaks with anti-γ-H2A antibodies
CA3033035C (fr) Methode de diagnostic de pancreatite aigue (ap) par detection d'isoforme alpha de glycoproteine 2 (gp2a)
JPH06502912A (ja) アナライト変異体分析
KR20060044621A (ko) 알돌라제를 포함하는 망막혈관 질환 진단용 조성물 및 그진단방법
EP1493034B1 (fr) Methode pour diagnostiquer des maladies inflammatoires et des infections par determination de lasp-1-immunoreactivite
JP3245052B2 (ja) Ｉ型プロコラーゲンのアミノ末端プロペプチドに対する抗体およびそれを用いるアッセイ法
JP2000515854A (ja) 脳タンパク質ｓ―１００の存在の測定方法
US8114607B2 (en) Type IV collagen-like immunoreactive peptide
WO1994010205A1 (fr) Proteine specifique de la maladie d'alzheimer et procede de diagnostic de cette maladie par detection de ladite proteine
CN107290552B (zh) 高凝血状态的生物标志物及其应用
KR101431067B1 (ko) 유방암 진단용 단백질 마커 아포리포단백질 （ａ）, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
JP2915530B2 (ja) ラミニン フラグメント
CA2351562A1 (fr) Procede de detection de lesions de cellules nerveuses par quantification des niveaux de map-2 dans des fluides biologiques
KR101431066B1 (ko) 유방암 진단용 단백질 마커 파이브로넥틴, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
KR101431063B1 (ko) 유방암 진단용 단백질 마커 아포리포단백질 ｃ-1, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트
TWI682175B (zh) 一種用於診斷胃癌的方法
Akhiani et al. Comparative antigen analysis of different life stages of Schistosoma mansoni by crossed immunoelectrophoresis
WO1995005395A1 (fr) Procede de diagnostic de la maladie d'alzheimer
Ibrahim et al. Detection of venoms from Egyptian elapids in experimentally envenomed mice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA